|
|
|
市場調查報告書
全球電燒技術市場（2009∼2019年）：產品、技術、市場、企業及技術
Ablation Technologies Worldwide Market, 2009-2019: Products, Technologies, Markets, Companies and Opportunities
|
全球電燒技術市場（2009∼2019年）：產品、技術、市場、企業及技術 是由出版商MedMarket Diligence在2010年06月所出版的。
這份英文市場調查報告書包含488 pages 價格從美金2850起跳。
本報告中針對治療軟組織的電燒技術及產品方面進行詳細分析，並由現在及未來應用領域、現狀與到2018年為止之預測、不同地區（南北美洲、歐洲、亞太地區）的市場趨勢、參與市場的主要企業之詳細介紹等交織而成，其概略內容如下所示。
實施概要
第一章 使用電燒切除技術治療之疾病
- 治療疾病的電燒技術概要
- 癌症
- 心血管疾病
- 眼科
- 一般外科
- 婦科
- 疼痛管理
- 泌尿科
- 整形外科
- 美容外科
第二章 產品及技術
- 冷凍療法
- 電氣能源
- 流力能源
- 光源
- 微波源
- 放射線源
- 射頻能源
- 熱源
- 超因波源
第三章 市場評估
- 全球市場概要
- 依產品分類之市場區隔
- 市場趨勢
- 全球市場中主要企業
- 國別市場
第四章 企業概況
第五章 主要臨床試驗
- 電氣
- 放射線
- 光
- 射頻
- 超音波
- 冷凍療法
- 熱
- 微波
- 流體力學
附錄
Abstract
This report is a detailed market and technology assessment and forecast of the
products and technologies in the ablation market for treatment of soft tissues
via energy-based modalities, including electrosurgery, radiosurgery, gamma
knife, brachytherapy, cryogenic therapy, fluidjet therapy (hydrotherapy),
microwave ablation, radiofrequency ablation, laser, thermal ablation, and
ultrasonic ablation.
The report describes alternative energy-based technologies and the nature of
their effect on soft tissue, the underlying basis of the technology, the
requisite systems for their use (including capital equipment, devices and
disposables), and their strengths and weaknesses for specific clinical
applications. The report details current and anticipated target applications
and assesses the current and forecast caseload for each energy-based
therapeutic considering competition from any and all alternative energy-based
or other therapeutics, with current and worldwide market forecasts (2009-2018)
segmented by technology type and specific clinical segment. The report
provides segmentation of the worldwide ablation market by both ablation
technology and region/country: Americas (USA, Canada, Mexico, Brazil), Europe
(Germany, United Kingdom, France, Italy, Spain, BeNeLux), Asia/Pacific (Japan,
China, India, Australia) and Rest of World. The report details the current and
emerging products, technologies and markets for each energy-based therapy. The
report profiles over 72 key companies in this industry detailing their current
products, current market position and products under development.
Report Statistics:
- 275 pages
- 75 Exhibits
- 83 Company Profiles
- May 2010
Methodology
MedMarket Diligence Reports are produced through primary and secondary
research. Data is gathered from published sources on products and technologies
on the market and under development. Clinicians and industry representatives
are interviewed for their knowledge and insights on product development,
market development, clinical practice and trends associated with the evolving
use of technologies. Secondary data is used to corroborate and support
assessments and projections. Reports are written and researched by industry
insiders, whose familiarity with the companies, industry dynamics and other
marketplace specifics facilitate the research process and ensure high quality
and thorough reports.
Table of Contents
Executive Summary
Section 1: DISEASE STATES TREATED WITH ENERGY-BASED ABLATIVE TECHNOLOGY
- 1.1 Overview of Ablation Technologies for the Treatment of Disease
- 1.1.1 Electrical
- 1.1.2 Radiation
- 1.1.3 Light
- 1.1.3.1 Lasers and their effect on tissue
- 1.1.3.2 Photodynamic therapy
- 1.1.4 Radiofrequency
- 1.1.4.1 Temperature controlled
- 1.1.4.2 Fluid cooled
- 1.1.5 Ultrasound
- 1.1.6 Cryotherapy
- 1.1.7 Thermal
- 1.1.8 Microwave
- 1.1.9 Hydromechanical
- 1.1.10 Technologies under development
- 1.2 Cancer
- 1.2.1 Breast
- 1.2.1.1 Current and Emerging Treatment Trends
- 1.2.1.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.2.2 Liver
- 1.2.2.1 Current and Emerging Treatment Trends
- 1.2.2.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.2.3 Lung
- 1.2.3.1 Current and Emerging Treatment Trends
- 1.2.3.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.2.4 Prostate
- 1.2.4.1 Gleason grades and scores
- 1.2.4.2 Prostate cancer staging
- 1.2.4.3 Current and Emerging Treatment Trends
- 1.2.4.4 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.2.5 Kidney
- 1.2.5.1 Current and Emerging Treatment Trends
- 1.2.5.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.3 Cardiovascular Disease
- 1.3.1 Angina Pectoris
- 1.3.1.1 Current and Emerging Treatment Trends
- 1.3.1.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.3.2 Atrial Arrhythmias
- 1.3.2.1 Current and Emerging Treatment Trends
- 1.3.2.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.3.3 Bradycardia
- 1.3.3.1 Current and Emerging Treatment Trends
- 1.3.3.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.3.4 Critical Limb Ischemia
- 1.3.4.1 Current and Emerging Treatment Trends
- 1.3.4.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.3.5 Critical Ischemic Stroke
- 1.3.5.1 Current and Emerging Treatment Trends
- 1.3.5.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.3.6 Hypertension
- 1.3.6.1 Current and Emerging Treatment Trends
- 1.3.6.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.3.7 Vascular Occlusive Disease
- 1.3.7.1 Current and Emerging Treatment Trends
- 1.3.7.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.3.8 Ventricular Arrhythmias
- 1.3.8.1 Current and Emerging Treatment Trends
- 1.3.8.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.3.9 Wolf-Parkinson-White Disease
- 1.3.9.1 Current and Emerging Treatment Trends
- 1.3.9.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.3.10 Varicose Veins
- 1.3.10.1 Current and Emerging Treatment Trends
- 1.3.10.2 Applicable Ablation Technologies: Rationale for Use and
Effect on Tissues
- 1.4 Ophthalmology
- 1.4.1 Cataracts
- 1.4.1.1 Current and Emerging Treatment Trends
- 1.4.1.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.5 General Surgery
- 1.5.1 Barrett' s Esophagus
- 1.5.1.1 Current and Emerging Treatment Trends
- 1.5.1.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.5.2 Fecal Incontinence
- 1.5.2.1 Current and Emerging Treatment Trends
- 1.5.2.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.5.3 Gastroesophageal Reflux Disease (GERD)
- 1.5.3.1 Current and Emerging Treatment Trends
- 1.5.3.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.5.4 Tonsillectomy
- 1.6 Gynecology
- 1.6.1 Menorrhagia
- 1.6.1.1 Current and Emerging Treatment Trends
- 1.6.1.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.6.2 Fibroids
- 1.6.2.1 Current and Emerging Treatment Trends
- 1.6.2.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.6.3 Stress Incontinence
- 1.6.3.1 Current and Emerging Treatment Trends
- 1.6.3.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.7 Pain Management
- 1.7.1.1 Current and Emerging Treatment Trends
- 1.7.1.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.8 Urology
- 1.8.1 Kidney Stones
- 1.8.1.1 Current and Emerging Treatment Trends
- 1.8.1.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.8.2 Benign Prostatic Hypertrophy (BHP)
- 1.8.2.1 Current and Emerging Treatment Trends
- 1.8.2.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.9 Orthopedics
- 1.9.1 Joint Instability (conducting Capsular Shrinkage)
- 1.9.1.1 Current and Emerging Treatment Trends
- 1.9.1.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.9.2 Carpal Tunnel Syndrome
- 1.9.2.1 Current and Emerging Treatment Trends
- 1.9.2.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.9.3 Chondroplasty
- 1.9.3.1 Current and Emerging Treatment Trends
- 1.9.3.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.9.4 Debridement
- 1.9.4.1 Current and Emerging Treatment Trends
- 1.9.4.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.9.5 Epicondylitis and Tendinitis
- 1.9.5.1 Current and Emerging Treatment Trends
- 1.9.5.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.9.6 Nucleoplasty
- 1.9.6.1 Current and Emerging Treatment Trends
- 1.9.6.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.9.7 Inflammatory Conditions
- 1.9.7.1 Current and Emerging Treatment Trends
- 1.9.7.2 Applicable Ablation Technologies: Rationale for Use and Effect
on Tissues
- 1.10 Aesthetic Treatments
- 1.10.1 Body Contouring
- 1.10.1.1 Current and Emerging Treatment Trends
- 1.10.1.2 Applicable Ablation Technologies: Rationale for Use and
Effect on Tissues
- 1.10.2 Laser Hair Removal
- 1.10.2.1 Current and Emerging Treatment Trends
- 1.10.2.2 Applicable Ablation Technologies: Rationale for Use and
Effect on Tissues
- 1.10.3 Laser Tattoo Removal
- 1.10.3.1 Current and Emerging Treatment Trends
- 1.10.3.2 Applicable Ablation Technologies: Rationale for Use and
Effect on Tissues
- 1.10.4 Port Wine Stains
- 1.10.4.1 Current and Emerging Treatment Trends
- 1.10.4.2 Applicable Ablation Technologies: Rationale for Use and
Effect on Tissues
- 1.10.5 Psoriasis
- 1.10.5.1 Current and Emerging Treatment Trends
- 1.10.5.2 Applicable Ablation Technologies: Rationale for Use and
Effect on Tissues
- 1.10.6 Scar Reduction and Removal
- 1.10.6.1 Current and Emerging Treatment Trends
- 1.10.6.2 Applicable Ablation Technologies: Rationale for Use and
Effect on Tissues
Section 2: PRODUCTS AND TECHNOLOGIES
- 2.1 Cryotherapy
- 2.1.1 Cardiac Cryoablation System (Cryocor)
- 2.1.2 Cryospray Ablation System (Csa Medical)
- 2.2 Electrical Energy
- 2.2.1 Electrosurgical Ablator
- 2.2.1.1 OrthoDynamix' ArthroSteer 3.5mm Ablator
- 2.2.2 Electrical Brachytherapy
- 2.3 Hydromechanical Energy
- 2.4 Light Energy
- 2.4.1 Cold Lasers
- 2.4.2 Excimer Lasers
- 2.4.2.1 Spectranetics' Turbo-Tandem System
- 2.4.3 Photonic Ablation
- 2.4.4 Ultraviolet B Lasers
- 2.4.5 Photoselective Vaporisation of the Prostate (PVP) for BHP
- 2.4.6 HoLAP for BHP
- 2.4.7 Indigo LaserOptic TreatmentR System for BHP
- 2.4.8 Laser In-Situ Keratomileusis (LASIK) for Cataracts
- 2.4.9 Laser Epithelial Keratomileusis (LASEK) for Cataracts
- 2.4.10 Ablative Fractional Resurfacing (Solta Medical)
- 2.5 Microwave Energy
- 2.5.1 CoreTherm for BHP
- 2.5.2 Prolieve for BHP
- 2.6 Radiation Energy
- 2.6.1 Brachytherapy
- 2.6.2 Stereotactic Radiosurgery (SRS)
- 2.6.2.1 Cyberknife
- 2.6.2.2 Gamma Knife
- 2.6.2.3 Axesse [used for both SRS and SBRT]
- 2.6.2.4 Novalis
- 2.6.2.5 Primatom
- 2.6.2.6 Synergy
- 2.6.2.7 X-Knife
- 2.6.2.8 TomoTherapy
- 2.6.2.9 Trilogy
- 2.6.3 Stereotactic Body Radiation Therapy (SBRT)
- 2.7 Radiofrequency Energy
- 2.7.1 TUNA for BHP
- 2.7.1.1 Prostiva RF Therapy
- 2.7.2 RF Ablation Catheters
- 2.7.2.1 Irrigated
- 2.7.2.2 Non-Irrigated
- 2.8 Thermal Energy
- 2.8.1 TMX 3000 for BHP
- 2.8.2 Water-Induced Thermotherapy for BHP
- 2.9 Ultrasonic Energy
- 2.9.1 Shock Wave Therapy
- 2.9.2 TUMT for BHP
- 2.9.3 Ultrasonic Surgical Systems
- 2.9.4 Spectrasonics' Tissue Parameter Imaging (TPI) technology
- 2.9.5 Non-invasive transcranial MR-guided focused ultrasound surgery
Section 3: MARKET ASSESSMENT
- 3.1 World Market Overview
- 3.2 Market Segmentation by Product Type
- 3.3 Market Trends
- 3.3.1 Market Drivers
- 3.3.1.1 Cardiac Arrhythmias
- 3.3.1.2 Cancer
- 3.3.1.3 Healthcare Economics
- 3.3.2 Market Restraints
- 3.3.2.1 Procedure Time
- 3.3.2.2 Cost of Capital Expenditure
- 3.3.2.3 Recession
- 3.4 Leading Companies in Global Market
- 3.5 Major National Markets
- 3.5.1 Americas
- 3.5.2 Europe
- 3.5.3 Asia/Pacific
- 3.5.4 Rest of World
Section 4: COMPANY PROFILES
- 4.1 Acoustic MedSystems
- 4.2 Accuray
- 4.3 Alcon Laboratories
- 4.4 American Medical Systems
- 4.5 Angiodynamics
- 4.6 Ardian, Inc.
- 4.6.1 Clinical Trials
- 4.6.1.1 Symplicity I Trial
- 4.6.1.2 Symplicity HTN-2 Trial
- 4.7 ArthroCare Corporation
- 4.8 AtriCure
- 4.9 ATS Medical
- 4.10 Bard Electrophysiology
- 4.11 Barrx Medical
- 4.12 Bausch & Lomb (Warburg Pincus)
- 4.13 Baylis Medical
- 4.14 Biocompatibles International plc
- 4.15 Biosense Webster
- 4.15.1.1 Irrigated Tip Catheter product lines
- 4.15.2 Clinical trials
- 4.15.2.1 NaviStar ThermoCool Catheter for the Treatment of AF - TX
Clinical Trial
- 4.15.2.2 CLARITY Clinical Study
- 4.15.2.3 Study of a New Catheter Using Force Sensing Capabilities for
the Treatment of AF and Ventricular Tachycardia (EZCF-125)
- 4.15.2.4 NaviStar ThermoCool Catheter for the Radiofrequency Ablation
of Drug Refractory Recurrent Symptomatic Paroxysmal AF Clinical Trial
- 4.16 Biotronik
- 4.17 Biowave
- 4.18 Boston Scientific
- 4.19 BSD Medical
- 4.19.1 Phase II MicroThermXR Microwave Ablation System (MTX-180)
- 4.19.2 BSD 500 Hyperthermia System
- 4.19.3 BSD-2000
- 4.20 Cardima
- 4.21 CardioFocus
- 4.21.1 Clinical Study of the CardioFocus Endoscopic Ablation System -
Adaptive Contact (CFEAS- AC) for the Treatment of Symptomatic Atrial
Fibrillation
- 4.22 CardioGenesis
- 4.23 Celon AG
- 4.23.1 Surgery/Radiology
- 4.23.2 Phlebology
- 4.24 Celsion
- 4.25 Chongqing Haifu (HIFU) Technology Co. Ltd.
- 4.26 ConMed
- 4.27 Covidien
- 4.27.1 Electrosurgery
- 4.27.2 VNUS Medical Technologies
- 4.27.2.1 ClosureFAST System
- 4.27.2.2 Model RFG2 Advanced Radiofrequency Generator
- 4.28 CryoCath (Medtronic)
- 4.29 CryoCor
- 4.30 CryoMedix
- 4.31 CSA Medical
- 4.32 Cynosure
- 4.33 Cytyc
- 4.34 Dornier MedTech
- 4.35 EDAP TMS S.A.
- 4.35.1 Ablatherm HIFU
- 4.35.2 Sonolith ESWL
- 4.36 Elekta
- 4.36.1 Leksell Gamma Knife 4
- 4.37 Endocare
- 4.38 Endophotonix
- 4.39 Endosense
- 4.39.1 TOCCATA Clinical Trial
- 4.40 Erbe
- 4.40.1 Electrosurgery
- 4.40.2 Water Jet Surgery
- 4.40.3 Cryosurgery
- 4.41 Ethicon Endo-Surgery
- 4.42 Focus Surgery
- 4.42.1 Clinical Trial
- 4.42.1.1 Organ Confined Prostate Cancer
- 4.43 Galil Medical
- 4.44 Getinge Group
- 4.44.1 Cardiac Surgery
- 4.44.2 Vascular Surgery
- 4.45 Gynesonics
- 4.46 Gyrus ACMI (an Olympus company)
- 4.47 Halt Medical
- 4.47.1 Clinical Trial
- 4.47.1.1 Laparoscopic Radiofrequency Ablation of Symptomatic Uterine
Fibroids (Halt Lap RFA)
- 4.48 HealthTronics Surgical Services
- 4.48.1 Medical Products
- 4.48.2 Urology Services
- 4.49 Hologic, Inc.
- 4.50 IBt-Bebig, SA
- 4.51 Initio, Inc.
- 4.52 InSightec
- 4.53 Medtronic
- 4.53.1 Cardiac Rhythm Disease Management (CRDM)
- 4.53.2 Spinal and Biologics
- 4.53.3 CardioVascular
- 4.53.4 Neuromodulation
- 4.53.5 Diabetes
- 4.53.6 Surgical Technologies
- 4.53.7 AF Solutions Franchise
- 4.53.8 Arctic Front Cardiac CryoAblation Catheter
- 4.53.9 Cardiac CryoAblation System
- 4.53.10 Clinical Trials
- 4.53.10.1 The STOP AF Clinical Trial
- 4.53.10.2 The TTOP AF Clinical Trial
- 4.53.10.3 The CURE-AF/Perst Clinical Trial
- 4.54 Mederi Therapeutics
- 4.54.1 Secca Procedure for fecal incontinence
- 4.54.2 Stretta Procedure for GERD
- 4.55 MedWaves
- 4.56 Mirabilis Medica
- 4.57 Misonix
- 4.58 NeuWave Medical
- 4.59 Novian Health
- 4.59.1 Clinical Trials
- 4.59.1.1 ABLATE (American Breast Laser Ablation Therapy Evaluation)
- 4.60 NuVue Therapeutics
- 4.61 Olympus Medical
- 4.62 OrthoDynamix
- 4.63 PhotoMedex
- 4.64 PhotoTherapeutics
- 4.65 PhotoThera
- 4.66 Radionics (Integra)
- 4.66.1 CoolTip RF Electrode
- 4.67 RFA Medical
- 4.68 Sanarus Technologies LLC
- 4.68.1 Cassi II Core Biopsy Device
- 4.68.2 ImarC Tissue Marker System
- 4.68.3 Visica 2 Treatment System
- 4.68.4 Clinical Trials
- 4.68.4.1 Z1072 Clinical Trial
- 4.69 Sirtex Medical
- 4.70 Smith & Nephew
- 4.71 Solta Medical
- 4.71.1 Ablative Fractional Resurfacing
- 4.72 Spectranetics
- 4.73 Spectrasonics
- 4.74 St. Jude Medical
- 4.74.1 Atrial Fibrillation
- 4.74.1.1 CABANA Clinical Trial
- 4.74.1.2 IRASE AF Clinical Trial
- 4.74.1.3 Modified stepwise Ablation Guided by low dose Ibutilide Use
in Chronic Atrial Fibrillation Trial (MAGIC-AF)
- 4.74.1.4 AFMAZE-CABG Clinical Trial
- 4.75 Starion Instruments
- 4.76 Stereotaxis
- 4.76.1 Stereotaxis Magnetic Navigation System
- 4.77 Synapse Biomedical
- 4.78 Theragenics
- 4.79 Urologix
- 4.80 USHIFU
- 4.81 Varian Medical Systems
- 4.81.1 RapidArc
- 4.81.2 Dynamic Targeting Image-Guided Radiation Therapy (IGRT)
- 4.81.3 SmartBeam IMRT
- 4.81.4 On-Board Imager
- 4.81.5 Dynamic Adaptive Radiotherapy (DART)
- 4.81.6 Image-Guided Brachytherapy (IGBT)
- 4.81.7 Varian Proton Therapy System
- 4.82 Visualase
- 4.83 Urologix
Section 5: key CLINICAL TRIALS
- 5.1 Electrical
- 5.2 Radiation
- 5.3 Light
- 5.3.1 Novian Health
- 5.3.1.1 ABLATE (American Breast Laser Ablation Therapy Evaluation)
- 5.3.2 CardioFocus
- 5.3.3 EndoPhotoniX
- 5.4 RadioFrequency
- 5.4.1 Ardian, Inc.
- 5.4.1.1 Symplicity I Trial
- 5.4.1.2 Symplicity HTN-2 Trial
- 5.4.2 AtriCure
- 5.4.3 Bard Electrophysiology
- 5.4.4 Biosense Webster
- 5.4.4.1 NaviStar ThermoCool Catheter for the Treatment of AF - TX
Clinical Trial
- 5.4.4.2 CLARITY Clinical Study
- 5.4.4.3 Study of a New Catheter Using Force Sensing Capabilities for
the Treatment of AF and Ventricular Tachycardia (EZCF-125)
- 5.4.4.4 NaviStar ThermoCool Catheter for the Radiofrequency Ablation
of Drug Refractory Recurrent Symptomatic Paroxysmal AF Clinical Trial
- 5.4.5 Halt Medical
- 5.4.5.1 Laparoscopic Radiofrequency Ablation of Symptomatic Uterine
Fibroids (Halt Lap RFA)
- 5.4.6 Medtronic
- 5.4.6.1 The CURE-AF/Perst Clinical Trial
- 5.4.6.2 The TTOP AF Clinical Trial
- 5.4.7 St. Jude Medical
- 5.4.7.1 CABANA Clinical Trial
- 5.4.7.2 IRASE AF Clinical Trial
- 5.4.7.3 Modified stepwise Ablation Guided by low dose Ibutilide Use in
Chronic Atrial Fibrillation Trial (MAGIC-AF)
- 5.5 Ultrasound
- 5.5.1 St. Jude Medical
- 5.5.1.1 AFMAZE-CABG Clinical Trial
- 5.6 Cryotherapy
- 5.6.1 Medtronic
- 5.6.1.1 The STOP AF Clinical Trial
- 5.6.2 Sanarus Medical Technologies LLC
- 5.6.2.1 Z1072 Clinical Trial
- 5.7 Thermal
- 5.8 Microwave
- 5.9 Hydromechanical
APPENDIX I: COMPANY DIRECTORY
APPENDIX II: RELEVANT ORGANIZATIONS
APPENDIX III: ABBREVIATIONS USED IN THIS REPORT
|
 |
